Ultragenyx (RARE) Received its Third Buy in a Row


After J.P. Morgan and Cowen & Co. gave Ultragenyx (NASDAQ: RARE) a Buy rating last month, the company received another Buy, this time from Raymond James. Analyst Laura Chico maintained a Buy rating on Ultragenyx today and set a price target of $57. The company’s shares opened today at $54.26.

According to TipRanks.com, Chico is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.6% and a 44.8% success rate. Chico covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Alexion Pharmaceuticals, and Paratek Pharmaceuticals.

Currently, the analyst consensus on Ultragenyx is a Strong Buy with an average price target of $70, a 29.0% upside from current levels. In a report issued on October 26, J.P. Morgan also maintained a Buy rating on the stock with a $68 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $90.98 and a one-year low of $41.67. Currently, Ultragenyx has an average volume of 523.3K.

Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. Last month, Shalini Sharp, the CFO & EVP of RARE bought 12,000 shares for a total of $9,720.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts